N/A N=545 Patterns of Care and Outcomes in Patients With Metastatic Bone Tumors (METABONE)
Metastatic Bone Tumor
Primary: Overall Survival (OS) — 21.5; 12.7; 26.6 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=29 Calcium Absorption in Patients With Rothmund-Thomson Syndrome
Rothmund-Thomson Syndrome
Primary: Bone Density (Low Areal Bone Mineral Density (aBMD)) — -1.3; -0.9; -2.4; -1.2 z-score
Phase 2 N=80 Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma
Sarcoma
Primary: Best Anatomical Tumor Response — 0; 2; 22; 30 participants
Phase 2 N=60 Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas
Sarcoma
Primary: Number of Participants With Engraftment — 23 Participants
Phase 2 N=21 Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI
Bone Cancer · Chondrosarcoma · Ewing's Sarcoma
Primary: T2* Relaxation Time of Bone Sarcomas and Osteomyelitis Subjects — 7.3; 7.7 milliseconds
Phase 2 N=11 Samarium Sm 153 and Stem Cell Transplant Followed By Radiation Therapy Patients With Osteosarcoma
Sarcoma
Primary: Tumor Response — 10 participants
N/A N=14 Stereotactic Radiation Therapy for Pediatric Sarcomas
Sarcoma · Metastatic Disease · Bony Sites
Primary: Lesion-specific Local Control at 6 Months Post-SBRT as Assessed by Percentage of Lesions Locally Controlled — 95 percentage of lesions
Phase 3 N=588 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
Adult Alveolar Soft-part Sarcoma · Adult Angiosarcoma · Adult Epithelioid Sarcoma
Primary: Probability for Event Free Survival. — 0.8984; 0.7647; 0.6079; 0.4873 Probability of EFS at 5 years
Phase 2 N=18 Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma
Sarcoma
Primary: Maximum Tolerated Dose (MTD) of Ra-223 Dichloride in Osteosarcoma — 100; 100 kBq/kg
N/A N=274 A Public Health Intervention Program to Improve the Initial Management of Soft Tissue Sarcomas.
Sarcoma
Primary: Adherence Rate to Diagnosis Imaging Guidelines for Patients With a Deep Sarcoma Tumor (Before Implementation of the Public Health Intervention Programme. — 145…
Phase 2 N=147 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
Adult Angiosarcoma · Adult Epithelioid Sarcoma · Adult Leiomyosarcoma
Primary: Overall Response Rate Measured by Complete Response (CR) Rate and Partial Response (PR) Rate as Determined by RECIST — 1; 0; 0; 0 participants
N/A N=70 Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas
Non-rhabdomyosarcoma Soft Tissue Sarcoma · Bone Sarcoma
Primary: Cumulative Incidence (Estimated Percentage of Participants) Who Developed Toxicities Following Radiation Treatment — 17.7 percentage of participants
Phase 2 N=98 Image-Guided Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Shoulder, Arm, Hip, or Leg
Lymphedema · Musculoskeletal Complications · Radiation Fibrosis
Primary: Rate of Late Radiation Morbidity (≥ Grade 2 Lymphedema, Subcutaneous Fibrosis, or Joint Stiffness) at 2 Years From the Start of Radiotherapy as Measured by EORTC/RTOG…
Phase 2 N=56 Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma
Metastatic Osteosarcoma · Recurrent Osteosarcoma · Refractory Osteosarcoma
Primary: Disease Control Rate (Cohort I) — 1 participants
Phase 2 N=51 S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas
Sarcoma
Primary: Objective Response (Confirmed, Complete and Partial) — 1; 0; 1; 8 participants
N/A N=9 (SBRT) and (ART) for Pulmonary Metastases From Soft Tissue Sarcomas
Stage IV Adult Soft Tissue Sarcoma · Sarcoma,Soft Tissue
Primary: Number of Adverse Events of Grade ≥ 3 by CTCAE Criteria. — 8 events
Phase 2 N=37 Sorafenib and Dacarbazine in Soft Tissue Sarcoma
Sarcoma · Synovial Sarcoma · Leiomyosarcoma
Primary: Overall Objective Response — 5; 22; 8 participants
Phase 2 N=20 Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma
Pleomorphic Rhabdomyosarcoma · Stage IIB Adult Soft Tissue Sarcoma AJCC v7 · Stage III Adult Soft Tissue Sarcoma AJCC v7
Primary: Pathologic Response Rate, Defined as the Percentage of Participants With Greater Than or Equal to 95% Necrosis. — 20 % of participants
Phase 2 N=16 Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation
Metastatic Soft Tissue Sarcoma
Primary: Part 2: Radiologic Progression-free Survival (PFS) — 18.7; 24.1 weeks — p== 0.6562
N/A N=63 Comparing Synthetic Bone Alone Versus Synthetic Bone With Bone Marrow in Bone Lesions
Bone Diseases
Primary: Resorption of Graft Material (GR) Compared at 24 Months — 51; 47 percentage of resorption — p=<0.01
Phase 2 N=71 Treatment of Patients With RAD001 With Progressive Sarcoma
Progressive Sarcoma
Primary: Best Overall Response Rates by Week 16 (ITT) — 0; 0; 0; 0 percentage of participants — p=0.1
Phase 2 N=15 Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)
Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor · Metastatic Osteosarcoma · Recurrent Adult Soft Tissue Sarcoma
Primary: Change in Fludeoxyglucose (FDG) Uptake (Maximal Standardized Uptake Value, or SUVmax)
Phase 2 N=54 Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma
Sarcoma
Primary: Objective Response Rate — 6; 5; 14 participants
Phase 2 N=43 A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma
Osteosarcoma · Malignant Fibrous Histiocytoma (MFH) of Bone
Primary: Number of Participants With Unacceptable Toxicity — 0; 0; 0; 0 participants
N/A N=2,165 Patterns of Care and Outcomes in METAstatic Soft Tissue SARComa
Sarcoma · Metastases · Chemotherapy
Primary: Correlation Between Time to Next Treatment (TNT) and Overall Survival (OS) Under First-line Treatment — 0.76 correlation coefficient
N/A N=70 Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers
Sarcoma · Thoracic Cancer · Abdominal Cancer
Primary: Rate of Local Control — 29 Participants
Phase 2 N=366 Trial of Dasatinib in Advanced Sarcomas
Rhabdomyosarcoma · Malignant Peripheral Nerve Sheath Tumors · Chondrosarcoma
Primary: Response Rate: Number of Participants With Objective Tumor Response — 12; 14; 20 Participants
Phase 2 N=5 BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases
Non Small Cell Lung Cancer With Bone Metastatses
Primary: Number of Symptomatic Skeletal Events (SSE) in Patients Receiving Xofigo With NSCLC and Bone Metastases — 1 Number of participants experiencing SSE
Phase 2 N=13 Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Sarcoma
Sarcoma
Primary: Number of Participants With Grade 3 Bilirubin — 3 participants with Grade 3 Bilirubin
Phase 2 N=53 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
Adult Malignant Fibrous Histiocytoma of Bone · Desmoid Tumor · Endometrial Cancer
Primary: Overall Objective Response — 1; 21; 26 participants